Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $19.00 at Royal Bank Of Canada

Sarepta Therapeutics (NASDAQ:SRPT) had its target price upped by Royal Bank Of Canada from $18.00 to $19.00 in a research report report published on Tuesday morning,MarketScreener reports. They currently have a sector perform rating on the biotechnology company’s stock.

SRPT has been the topic of several other research reports. Loop Capital set a $25.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 3rd. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Sarepta Therapeutics from $12.00 to $14.00 and gave the stock a “sell” rating in a research note on Thursday, March 26th. Wall Street Zen raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Needham & Company LLC reissued an “underperform” rating on shares of Sarepta Therapeutics in a research note on Thursday, March 26th. Finally, Citigroup boosted their price objective on shares of Sarepta Therapeutics from $9.00 to $13.00 and gave the stock a “sell” rating in a research note on Thursday, March 26th. Nine equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $32.63.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT traded down $0.35 during midday trading on Tuesday, reaching $22.73. 501,253 shares of the company were exchanged, compared to its average volume of 2,943,143. The stock’s 50-day moving average price is $18.79 and its 200-day moving average price is $20.26. The stock has a market cap of $2.39 billion, a P/E ratio of -2.71, a PEG ratio of 0.36 and a beta of 0.29. Sarepta Therapeutics has a one year low of $10.41 and a one year high of $64.80. The company has a quick ratio of 1.48, a current ratio of 2.32 and a debt-to-equity ratio of 0.73.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The company had revenue of $442.93 million for the quarter, compared to the consensus estimate of $390.95 million. During the same period in the previous year, the firm posted $1.90 EPS. The business’s quarterly revenue was down 32.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the sale, the director owned 1,765 shares of the company’s stock, valued at approximately $30,040.30. This represents a 80.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 7.60% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Sarepta Therapeutics by 9.2% during the fourth quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company’s stock valued at $254,167,000 after acquiring an additional 993,283 shares during the last quarter. AQR Capital Management LLC boosted its position in Sarepta Therapeutics by 454.6% during the fourth quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock valued at $167,781,000 after acquiring an additional 6,390,860 shares during the last quarter. Erste Asset Management GmbH boosted its position in Sarepta Therapeutics by 1.6% during the fourth quarter. Erste Asset Management GmbH now owns 2,728,945 shares of the biotechnology company’s stock valued at $58,727,000 after acquiring an additional 43,000 shares during the last quarter. Aberdeen Group plc boosted its position in Sarepta Therapeutics by 13.6% during the fourth quarter. Aberdeen Group plc now owns 2,251,593 shares of the biotechnology company’s stock valued at $48,454,000 after acquiring an additional 268,829 shares during the last quarter. Finally, First Trust Advisors LP boosted its position in Sarepta Therapeutics by 2.7% during the fourth quarter. First Trust Advisors LP now owns 1,992,577 shares of the biotechnology company’s stock valued at $42,880,000 after acquiring an additional 52,796 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.